LUMA Vision
- Industry
- Medical Devices
- Founded Year
- 2017
- Headquarters
- Dublin, Ireland
- Employee Count
- 50
Key People
- Fionn Lahart - Co-Founder & Chief Executive Officer
- Christoph Hennersperger - Co-Founder & Chief Technology Officer
- David Smyth - Chief Financial Officer
- Marta Walker - Director of Quality & Regulatory
- Steve Davies - Director of Hardware
- Sascha Dorenbeck - Director of Software
- Dr. Torsten Scheuermann - Director of Advanced Projects
- Dr. Stefan Wrz - Head of Computer Vision & Algorithmics
- Dr. Cdric Assambo - Head of Systems
- David Keller - Head of Mechanical Engineering
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and engineering.
The co-founders, Fionn Lahart and Christoph Hennersperger, bring substantial expertise in medical device development and commercialization, enhancing the company's potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: LUMA Vision addresses a critical need for advanced cardiac imaging solutions to improve procedural outcomes.
The VERAFEYE platform offers real-time, high-resolution imaging, potentially reducing complications and improving patient outcomes in cardiac procedures.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for cardiac imaging devices includes several established players.
While LUMA Vision's technology is innovative, it competes with other companies offering advanced imaging solutions, necessitating strong differentiation and strategic positioning.
- Technical Challenge
-
Aspect: Complex
Summary: Developing and integrating real-time 4D imaging technology presents significant technical challenges.
The complexity of creating a system that provides accurate, real-time imaging of the heart requires advanced engineering and substantial R&D investment.
- Patent
-
Aspect: Strong
Summary: LUMA Vision has secured patents to protect its innovative imaging technology.
The company's intellectual property portfolio strengthens its competitive position and provides barriers to entry for potential competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has raised substantial funding from reputable investors.
With a $22 million Series A3 financing round in December 2023, LUMA Vision is well-capitalized to advance product development and commercialization efforts.
- Regulatory
-
Aspect: 510k/PMA
Summary: LUMA Vision has achieved FDA clearance for its VERAFEYE platform.
The FDA clearance in April 2025 marks a significant milestone, allowing the company to market its product in the U.S. and demonstrating compliance with regulatory standards.
Opportunity Rollup
- Odds of Success
- 3.3
- Peak Market Share
- 4.2
- Segment CAGR
- 4.5%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Electrophysiology Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.21 |
| 2 | 0.63 |
| 3 | 1.47 |
| 4 | 2.94 |
| 5 | 4.20 |
Key Takeaway
LUMA Vision's innovative VERAFEYE platform addresses a critical need in cardiac imaging, supported by a strong team and substantial funding, positioning the company well in a competitive market.